Kuo-Hsuan Hsu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Systemic Sclerosis

Top Venues

Therapeutic advances in medical oncology

OncoTargets and therapy

International journal of molecular sciences

Cancer management and research

This page only lists publications with an associated author ORCID identifier.

Publications

Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 16 (2024)
Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 16 (2024)
Po-Hsin Lee, Wei-Fan Ou, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination. International journal of molecular sciences 25 (13) (2024)
Po-Hsin Lee, Wei-Fan Ou, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination. International journal of molecular sciences 25 (13) (2024)
Wei-Fan Ou, Pei-Ya Liao, Yu-Wei Hsu, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy. Cancer management and research 15 (2023)
Kuan-Chih Chen, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, Tsung-Ying Yang
The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR -Mutant NSCLC Patients Treated with First-Line Osimertinib. OncoTargets and therapy 16 (2023)
Kuo-Hsuan Hsu, Jing-Wen Huang, Jeng-Sen Tseng, Kuan-Wen Chen, Yih-Chyang Weng, Sung-Liang Yu, Tsung-Ying Yang, Yen-Hsiang Huang, Jeremy J W Chen, Kun-Chieh Chen, Gee-Chen Chang
Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients. OncoTargets and therapy 14 (2021)
Yen-Hsiang Huang, Jen-Yu Hung, How-Wen Ko, Po-Lan Su, Chun-Liang Lai, Huang-Chih Chang, Te-Chun Hsia, Sheng-Hao Lin, Kuan-Li Wu, Cheng-Ta Yang, Wu-Chou Su, Yi-Chun Chu, Chin-Chou Wang, Wei-Yu Liao, Yen-Ting Lin, Ching-Hsiung Lin, Meng-Chih Lin, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Mei-Hsuan Lee, Sung-Liang Yu, Chao-Chi Ho, Gee-Chen Chang
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Therapeutic advances in medical oncology 13 (2021)